Broadens Merck Animal Health’s Position with
Enhanced Parasite Protection in Calves and Lambs
Merck Animal Health, known as MSD Animal Health outside the
United States and Canada, a division of Merck & Co., Inc.,
Kenilworth, N.J., USA (NYSE:MRK), today announced the completion of
its previously announced acquisition of the worldwide rights to
VECOXAN® (diclazuril), an oral suspension for the prevention of
coccidiosis in calves and lambs, from Elanco Animal Health.
VECOXAN is efficacious, in lambs, against the prevention of
coccidiosis caused by Eimeria crandallis and Eimeria ovinoidalis,
and in calves, against coccidiosis caused by Eimeria bovis and
Eimeria zuernii. VECOXAN is available in Europe, South Africa,
South Korea and Japan.
Parasite control and protection is an essential and significant
part of ruminant overall health management and outcomes. “With
advanced digital and diagnostic solutions to manage the welfare of
animals as critical components of our technology, we are dedicated
to advancing the health and well-being of animals and the people
who take care of them,” said Rick DeLuca, president, Merck Animal
Health. “This complementary product for youngstock will add to our
existing portfolio of veterinary medicines, including
parasiticides, vaccines and services, which provides a full range
of complementary solutions for our customers, and underscores our
commitment to The Science of Healthier Animals®.”
Coccidiosis, a common cause of scours (diarrhea) in lambs and
calves that is highly prevalent on cattle and sheep farms, is
caused by protozoan parasites called Eimeria that multiply in the
intestinal wall, transmitted from animal to animal by the
fecal-oral route. Clinical signs include painful scours with or
without blood, and decreased appetite and depression, which may
progress to dehydration and weight loss. Coccidiosis primarily
affects young animals; calves and lambs as young as three to four
weeks of age may be affected.
Coccidiosis causes significant economic loss to farmers and
producers due to reduced feed conversion, reduced growth rates,
reduced performance or death, and by increased susceptibility to
other infections, such as intestinal disease or Bovine Respiratory
Disease.
About VECOXAN
VECOXAN is an anticoccidial of the benzeneacetonitrile group
without antimicrobial activity and has anticoccidial activity
against Eimeria species. The product can be used in calves and
lambs, beef and dairy, of any weight, in any management system,
without environmental restrictions. It has a zero-day meat
withdrawal period.
About Merck Animal Health
For more than a century, Merck, a leading global
biopharmaceutical company, has been inventing for life, bringing
forward medicines and vaccines for many of the world’s most
challenging diseases. Merck Animal Health, a division of Merck
& Co., Inc., Kenilworth, N.J., USA, is the global animal health
business unit of Merck. Through its commitment to The Science of
Healthier Animals®, Merck Animal Health offers veterinarians,
farmers, pet owners and governments one of the widest ranges of
veterinary pharmaceuticals, vaccines and health management
solutions and services as well as an extensive suite of digitally
connected identification, traceability and monitoring products.
Merck Animal Health is dedicated to preserving and improving the
health, well-being and performance of animals and the people who
care for them. It invests extensively in dynamic and comprehensive
R&D resources and a modern, global supply chain. Merck Animal
Health is present in more than 50 countries, while its products are
available in some 150 markets. For more information, visit
www.merck-animal-health.com or connect with us on LinkedIn,
Facebook, and Twitter at @MerckAH.
Forward-Looking Statement of Merck & Co., Inc.,
Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J.,
USA (the “company”) includes “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These statements are
based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties.
If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of the recent global outbreak of novel coronavirus
disease (COVID-19); the impact of pharmaceutical industry
regulation and health care legislation in the United States and
internationally; global trends toward health care cost containment;
technological advances, new products and patents attained by
competitors; challenges inherent in new product development,
including obtaining regulatory approval; the company’s ability to
accurately predict future market conditions; manufacturing
difficulties or delays; financial instability of international
economies and sovereign risk; dependence on the effectiveness of
the company’s patents and other protections for innovative
products; and the exposure to litigation, including patent
litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company’s 2019
Annual Report on Form 10-K and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200803005143/en/
Merck Media: Hester de Voogd +1 (201) 463-0407
Hester.de.voogd@merck.com
Pam Eisele +1 (267) 305-3558 Pamela.Eisele@merck.com
Merck Investors: Michael DeCarbo + 1 (908) 740-1807
Michael.DeCarbo@merck.com
Merck (NYSE:MRK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Sep 2023 to Sep 2024